|
|
|
SLS Description — SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers.
Company Name: |
SELLAS Life Sciences Group Inc |
Website: |
www.sellaslifesciences.com |
Sector: |
Biotechnology |
Number of ETFs Holding SLS: |
5 |
Total Market Value Held by ETFs: |
$2,100,252 |
Total Market Capitalization: |
$49,000,000 |
% of Market Cap. Held by ETFs: |
4.29% |
|
ETF |
SLS Weight |
SLS Amount |
VTI |
0.00% |
$1,413,800 |
VXF |
0.00% |
$540,646 |
IWC |
0.01% |
$77,861 |
GWX |
0.01% |
$66,858 |
SPGM |
0.00% |
$1,087 |
|
|
|
|
Strong Buy (4.00 out of 4)
80th percentile
|
|
|